Friday The Thirteenth

Eeck. Offsetting the superstition, the John Lewis Partnership, which was founded by his relatives, reported excellent results yesterday, although the family no longer owns the department store group. It was given to the employees by my husband's cousin Spedham Lewis and the family are no longer the gainers.

*The stock week in points eastward was mixed. The USA markets I think faces a bear correction. Mexico is riding high according to Eduardo Garcia, editor of, thanks to IMF funding and a high inflow from US investors and funds. 

*Nintendo NTDOY, the gaming site, was the top loser in Japan. A top winner was Sumitomo Mitsui Finance SMFG. The bullish list in Europe included Royal Dutch Shell B RDS-B, reacting to the Biden search for more oil for the US. 

*Schlumberger Ltd. rose on likely higher wildcat spudding by oil companies under the Biden program aiming to get more fuel out. SLB.

Business newspaper article

image source


*UK brokerage Baillie Gifford has dropped Tesla stock coverage. NIO, my favorite electric car-maker, reported a loss of 7 cents/sh on sales of $1.36 mn in Q2, both ahead of consensus and there were heavy forward options in the premarket, up 2%. However analysts were mostly positive, with minor cuts in target prices, Citi's Jeff Chung now calls for a TP of $70, down $2, but a 57% rise from current levels. BofA's Ming Hsun Lee expects sales to rise 5% and Mizuho's Vijay Rakesla has a $65 TP. The only negativist is Fei Fang of Goldman Sachs who rates Nio a hold. 

*Manulife, a sub of John Hancock, the US insurance firm, is buying a chunk of Maine timberland. This bodes well for Weyerhaeuser of Canada, a fund-owning forests we own. I bought more WY.


*The prospect of a weekend took TEVA down below $10.

*Organon OGN, the spinoff from Merck MRK tipped by Jack Hough in Barrons as the second cheapest share in the S&P 500, has begun moving upward.

*Glaxo is up on forecasts that its shingles vaccine will be a best-seller among the old who got it from a childhood bout with chickenpox. GSK.

*Takeda was downed to bearish in Japan. TAK.

*Bioline RX reports on Q2 Aug. 18. BLRX.

*I bought more Novacure NVCR at $141.43 after its failure to eliminate liver cancer with its electric system. It fell further. I earlier added to my Enlivex ENLV which rose 5.31% to $10.3.


Sumitomo Mitsui, a financial conglomerate stock was rated bullish. SMFG.

*Sampo Oyj gained 0.8% in Finland. SAXPY.

*A share we exited, Australian Orocobre, which mines lithium in Argentina, merged with Galaxy for A$4 bn as Galaxy shareholders get .569 ORO shares for every on their own in Galaxy.

*Azure Power will issue 144 (professional) green 5-yr bonds paying 3.575%, a new low-interest rate, and it also sold off 19.4% of its shares to the IFC, the private arm of the World Bank, raising more money. AZRE.

*Ghastly Korean Coupang, CPNG, reported Q2 EPS and sales below consensus and the shares fell $7.55. However, Lazard, LAZ, gained 0.18. This is good given their Jewish heritage as the Hebrew letters of 18 spell life, a lucky number.

*My blog yesterday from London gave the wrong US ticker symbol for SSE Plc. It is SSEZY. Sorry. The UK uses a different one. I managed to buy it in my US account at $22.24/sh, rather higher than expected. 

*Mercado Libre, MELI, got a new much higher eps target for the Sept quarter, up 7% to $1.267/sh but the stock fell all the same.

*Hoegh fell sharply as US lawsuits against its parent for taking over orders were filed in the US. HMLP.

How did you like this article? Let us know so we can better customize your reading experience.